Latest filing published 03 Sept 2026 for Autolus Therapeutics plc, €40k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Cintia Piccina discloses dealings in 3 companies, chiefly Adaptimmune Therapeutics PLC, Autolus Therapeutics plc and Kalaris Therapeutics, Inc. Over a trading history stretching from 1 August 2022 to 2 September 2026, the count stands at 7 filings.
No open-market purchase appears, only 5 sales worth €99k. The rest of the record consists of 1 share grant and 1 option exercise. In 2026 alone, the filings show no purchases and 1 sale.
The latest filing, published on 3 September 2026, reports an option exercise of €40k in Autolus Therapeutics plc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 of 7 declarations